-
ArticlePublication 2016Cost-Effectiveness of a Herpes Zoster Vaccination Program among the French Elderly People
This study reports on a cost-effectiveness analysis of herpes zoster (HZ) vaccines among the elderly …
This study reports on a cost-effectiveness analysis of herpes zoster (HZ) vaccines among the elderly in France. Starting vaccination in individuals aged 65, 70 and 75 years old appears more cost-effective than vaccination for beginning vaccination at age 60, with a cost-effectiveness ratio between 30,000 and 35,000 euros per quality-adjusted-life year (QALY) gained for the 65 and 70-year age groups versus 54,500 euros for the age 75 group. These results largely contributed to the recommendation…
Economics/Finance | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | Europe -
NewsPublication 2017C.D.C. Panel Recommends a New Shingles Vaccine
In a New York Times report, the Centers for Disease Control and Prevention recommended the …
In a New York Times report, the Centers for Disease Control and Prevention recommended the use of a new vaccine to prevent herpes zoster (“shingles”) among adults in the US. “In an unusually close vote, an advisory panel to the Centers for Disease Control and Prevention on Wednesday recommended the use of a new vaccine to prevent shingles over an older one that was considered less effective. "The decision was made just days after the…
Economics/Finance | Infectious Diseases | Health Systems | Policy/Regulation | Health/Medicine | Science/Technology | North America -
NewsPublication 2017FDA Advisers Recommend Approval of New Shingles Vaccine
An FDA advisory panel voted 11-0 on Wednesday in favor of approving the Shingrix herpes …
An FDA advisory panel voted 11-0 on Wednesday in favor of approving the Shingrix herpes zoster vaccine for adults aged 50 and older, Reuters reports. In clinical trials, the new vaccine conferred greater protection against herpes zoster among older adults, relative to the currently marketed zoster vaccine, Zostavax. In particular, 4 years after immunization, Shingrix was about 90% effective in adults older than 70, while the efficacy of Zostavax waned with time, according to Reuters.…
Economics/Finance | Infectious Diseases | Policy/Regulation | Government/Law | Health/Medicine | North America -
ArticlePublication 2017Analysis of Real-World Health Care Costs among Patients Aged 50 Years or Older with Herpes Zoster
This article reports on the direct costs associated with herpes zoster (HZ) and postherpetic neuralgia …
This article reports on the direct costs associated with herpes zoster (HZ) and postherpetic neuralgia (PHN) in the U.S. The authors use a retrospective managed care insurance claims database of 142,519 patients with herpes zoster (9,470 patients [6.6%] had postherpetic neuralgia) and 357,907 matched controls. They found that resource utilization was greater among patients with herpes zoster: after adjusting for demographic and clinical characteristics, annual incremental health care costs for herpes zoster patients vs. controls…
Economics/Finance | Costing Methods | Evidence Synthesis | Infectious Diseases | Health/Medicine | North America -
ReviewPublication 2013Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination
This review summarized the herpes zoster (HZ) vaccination cost effectiveness literature, consisting of 11 studies …
This review summarized the herpes zoster (HZ) vaccination cost effectiveness literature, consisting of 11 studies Most studies evaluated the cost effectiveness of universal HZ vaccination in adults aged 50 years or 60 years and older and all studies calculated costs per QALY. The costs per QALY gained and the incremental cost-effectiveness ratio (ICER) differed depending on the age at vaccination, duration of vaccine efficacy, cost of vaccine course, and economic perspective. All but one of…
Economics/Finance | Preferences/Values | Cost-Effectiveness Analysis | Infectious Diseases | Clinical Care | Health/Medicine | North America -
Working PaperPublication 2017Cost-Effectiveness Analysis of Adjuvanted Subunit Vaccine for Prevention of Herpes Zoster
Herpes zoster (HZ) develops in up to 50% of unvaccinated individuals who live to 85 …
Herpes zoster (HZ) develops in up to 50% of unvaccinated individuals who live to 85 years of age, accounting for more than 1 million cases of HZ annually in the United States. A live attenuated vaccine (LAV) for HZ is U.S. FDA approved for persons 50 years or older, though CDC Advisory Committee on Immunization Practices (ACIP) recommendations are only for persons beginning at age 60 years. LAV efficacy at preventing HZ is ~70% for…
Economics/Finance | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | North America
6 Shown
General Resources
Teaching Resources
Collections
Format
Learner Level
Teaching Topic